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DOI 10.1016/j.ccr.2010.03.019SUMMARYThe retinoblastoma (Rb) tumor suppressor is often inactivated in cancers. To identify genes that can be used
to specifically target such cancers, we carried out a genetic screen in Drosophila. We identified gig (fly TSC2)
and found that inactivation of rbf (fly Rb) and gig synergistically induced cell death. Interestingly, inactivation
of TSC2 specifically kills Rbmutant cancer cells under stress conditions, which is correlatedwith an inhibition
of tumor growth. We show that cancer cell killing induced by concomitant inactivation of Rb and TSC2 is
mediated by increased cellular stress, including oxidative stress. Inactivation of TSC2 and Rb synergistically
induce oxidative stress via increased protein synthesis, inhibited de novo lipid synthesis, and decreased
reactive oxygen species scavenger enzyme SOD2 induction.INTRODUCTION
The success of a targeted cancer therapy depends on its ability
to target the unique features of tumor cells that are distinct from
those of the normal cells. For example, the efficacy of androgen
ablation therapy for early prostate cancers is due to the special
dependence of prostate cancer cells on androgen for growth,
proliferation, and survival (Balk and Knudsen, 2008). Similarly,
the effectiveness of imatinib for Philadelphia chromosome-
positive chronic myeloid leukemia (CML) is due to the unique
dependence of these CML cells on Bcr-Abl kinase activity, which
is specifically inhibited by imatinib (Druker, 2002).
The changes acquired by cancer cells that contribute to their
uncontrolled proliferation and growth often include both deregu-
lated oncogenic pathways as well as inactivated tumor
suppressor pathways (Hanahan and Weinberg, 2000). Current
strategies to develop targeted cancer therapies generally aim at
components of signaling pathways that are deregulated or
required in cancer cells, such as specific kinases. Studies of
gefitinib, an inhibitor of epidermal growth factor receptor (EGFR)
tyrosine kinases, revealed that this inhibitor is only effective on
a small subset of cancers that exhibit mutations or amplificationsSignificance
Although cancer cells often exhibit inactivation of tumor suppre
develop targeted cancer therapies. Based on the observations
inactivation of TSC2 specifically kills Rb mutant cancer cells a
gistically induced by the inactivation of Rb and TSC2 and in
TSC2 is a target that can be used to specifically kill Rb-deficie
cancers.that deregulate EGFR signaling (Lynch et al., 2004; Mulloy et al.,
2007; Paez et al., 2004). In addition, cancers resistant to this
therapy eventually develop (Engelman and Janne, 2008). These
observations suggest the need to have an array of drugs that
target different features of cancer cells such that different combi-
nations can be used to specifically target different subsets of
cancers and prevent the development of resistant cancers.
In addition to deregulated oncogenic activity, cancer cells
often acquire inactivation of tumor suppressors such as the reti-
noblastoma protein Rb. Although approaches that specifically
target loss of Rb function in cancers are potentially useful to
a significant fraction of human cancers, there has been little
success in developing therapies by targeting loss of Rb function
in cancers. This is mainly due to the lack of straightforward
approaches to restore the Rb function in all cancer cells and
the lack of knowledge of so-called synthetic lethal genes that
are specifically required for the survival of cancer cells with inac-
tivated Rb tumor suppressors. The lack of knowledge about
synthetic lethal genes in conjunction with the lack of suitable
approaches to identify such genes has limited the development
of drugs that could specifically kill cancer cells based on the
inactivated tumor suppressors.ssors such as Rb, such knowledge has yet to be exploited to
from our genetic screen in Drosophila, we demonstrate that
nd inhibits tumor growth. We show that cell death is syner-
volves increased cellular stress. Our results suggest that
nt cancers, which will be a significant fraction of all human
Cancer Cell 17, 469–480, May 18, 2010 ª2010 Elsevier Inc. 469
Figure 1. Inactivation of Cell Death Regula-
tors hid or dronc Increases the Sizes of
gig,rbf Double-Mutant Clones
Images shown are of adult eyes mosaic for mutant
(white) and wild-type (red) tissues of the indicated
genotypes. Significant amounts ofmutant patches
were observed in gig single (C and K), but not in
rbf,gig double, mutants (D and L). Removing cell
death regulators dronc or hid (E-J, M-N) restores
rbf,gigmutant patches. The rbf,gig double-mutant
phenotype is also reversed in a de2f1 mutant
background (O). Scale bar represents 100 mm.
See also Figure S1.
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Specific Killing of Rb Mutant Cancer CellsRb regulates diverse biological processes including cell prolif-
eration, differentiation, and apoptosis. The biological functions
of Rb are mediated by its interactions with a large number of
proteins, particularly the E2F family of transcription factors. Rb
and E2F regulate the expression of genes involved in the cell
cycle as well as apoptosis (reviewed in Bracken et al., 2004;
Iaquinta and Lees, 2007). Rb and E2F have been shown to
regulate apoptosis through a number of different mechanisms.
E2F1 overexpression can induce apoptosis via transcriptional
activation of proapoptotic genes including Arf, p73, APAF-1,
Smac/Diablo, Omi HTRA2, and BH3 only-containing cell death
regulators. E2F can also induce the expression of initiator and
effector caspases (Nahle et al., 2002). Additionally, Rb and E2F
have been shown to control the accumulation of reactive oxygen
species (ROS) and thereby regulate cell death through a mecha-
nism involving oxidative stress (Tanaka et al., 2002).
Rb/E2F-induced cell death is modulated by other regulators
and signaling pathways such as the growth factor-stimulated
activation of PI3K and Akt survival signaling (Hallstrom et al.,
2008; Hallstrom and Nevins, 2003). It is interesting to note that
in addition to their role in survival signaling, PI3K/Akt also has
a major role in the regulation of energy metabolism and the
coordination of key metabolic pathways (Robey and Hay,
2009). Akt has been shown to regulate mTOR signaling by direct
phosphorylation and inhibition of Tuberin, the gene product of
the TSC2 tumor suppressor (Inoki et al., 2002; Potter et al.,
2002). Because elevated Akt activity induces increased ROS
accumulation, activation of PI3K/Akt can inhibit cell death
induced by a variety of stimuli but not by oxidative stress. In
fact, hyperactivity of Akt sensitizes cells to ROS-induced cell
death (Nogueira et al., 2008).
The Rb and E2F proteins are highly conserved in Drosophila
(reviewed in Du and Pogoriler, 2006). There are only two470 Cancer Cell 17, 469–480, May 18, 2010 ª2010 Elsevier Inc.E2F (dE2F1 and dE2F2), one DP (dDP),
and two Rb family (RBF and RBF2) genes
in the Drosophila genome. Interestingly,
dE2F1 functions similar to the mamma-
lian activating E2Fs, whereas dE2F2
behaves like the repressive E2F proteins.
RBF, which binds to both dE2F1 and
dE2F2, is similar to the mammalian
Rbprotein and regulates cell proliferation,
differentiation, and apoptosis in Dro-
sophila (Du, 2000; Du and Dyson, 1999;Moon et al., 2006; Steele et al., 2009; Tanaka-Matakatsu et al.,
2009).
The high conservation of the Rb pathway between Drosophila
and mammalian systems prompted us to carry out a genetic
screen to identify genes that can modulate the consequences
of Rb inactivation (Steele et al., 2009; Tanaka-Matakatsu et al.,
2009).
RESULTS
Mutation of gig and rbf Leads to Synergistic Induction
of Cell Death
In a genetic screen formutations thatmodulate the consequence
of rbf inactivation, we identified a mutation, 64. Whereas muta-
tion of 64 alone led to large mutant patches in adult eyes,
mutation of 64 in conjunction with rbf led to only very small
mutant patches (Figures 1A–1D). In addition, adult eyes with
rbf,64 double mutant clones were smaller and displayed a rough
appearance.
The decreased size of rbf,64 double-mutant clones could
be due to an effect of the two mutations on cell proliferation or
cell death. Examination of DNA replication showed no inhibition
of proliferation (data not shown). Therefore, activated caspase-3
(C3) was used to examine the level of cell death. Consistent with
previous reports (Du, 2000;Moon et al., 2006), mutation of rbf led
to increased apoptosis near the morphogenetic furrow (MF)
(Figure 2A). Although mutation of 64 alone did not cause
significant C3 activation in eye discs, mutation of 64 in conjunc-
tion with rbf mutation significantly expanded the observed
apoptosis to both anterior aswell as posterior clones in eye discs
(Figures 2A–2C, arrows) and increased the overall level of cell
death in clones throughout the eye disc (Figure 2N). Further-
more, the synergistic induction of cell death by rbf and 64
Figure 2. Synergistic Induction of Cell
Death by Mutations of rbf and gig
(A–C) Mutant clones of the indicated genotypes
are marked by the absence of GFP. Activated cas-
pase-3 (C3) staining shows the pattern of cell
death in rbf (A), gig64 (B), and rbf,gig64 (C) mutant
clones. Mutation of gig significantly enhances
the phenotype caused by loss of rbf in clones
both anterior (yellow arrows) and posterior (white
arrows) to the MF. (D–G) Synergistic death
requires both hid (D) and dronc (E) in posterior,
but not anterior, cells. The cell death phenotype
of rbf,gig double mutants requires de2f1 (F) and
ds6k (G). (L–M) images of adult eyes with
rbf,gig64,ds6k or rbf,gig192,ds6k triple mutant
clones. Enhanced cell death is also observed in
rbf,gig clones during wing development (H–J).
Quantification of cell death within mutant clones
is shown for eye (N) and wing (O) tissues. (K, top
panel) Expression of Puc in the posterior of wing
disc using the engrailed-Gal4 driver significantly
decreased cell death, which is quantified in (P).
(K, bottom panel), Ci, which is expressed in the
anterior of wing discs, is used to define anterior
posterior boundary. Asterisks indicate statistically
significant differences between double and single
mutant clones (*) or double versus triple mutant
clones (**). Error bars indicate standard deviation
(SD). All discs are oriented with anterior to the
left. Scale bar, 100 mm.
See also Figure S2.
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was slightly increased in 64 mutant clones but not in rbf single
mutant clones. Significantly increased C3 staining was observed
in rbf,64 double mutant clones (Figures 2H–2J and 2O). These
results indicate that inactivation of rbf and 64 leads to synergistic
induction of cell death in both wing and eye discs.
Deficiency mapping revealed that the 64 mutation lies
between 76F-77B. The following evidence showed that the 64
mutation is an allele of gig, the Drosophila TSC2 homolog: (1)
64 mutation failed to complement a previously identified gig
allele, gig192; (2) the mutant phenotypes of 64 and rbf,64 clones
in adult eyes are very similar to those of the gig192 and rbf,gig192
clones (Figures 1C, 1D, 1K, and 1L); (3) sequencing of the gig
gene in 64 mutant identified a C to T mutation that gives rise to
a stop codon after amino acid 431 (see Figure S1 available on-
line); and (4) rbf,gig192 double mutant clones also show syner-
gistic induction of cell death in both the developing eye and
wing discs (Figure S2). Therefore we renamed the 64 mutant
gig64. Because gig64 does not encode the functional domains
of gigas, it is likely that gig64 constitutes a null allele.
rbf,gig-Induced Cell Death in the Anterior and Posterior
Parts of the Eye Disc Exhibit Differential Requirements
for Hid and Dronc
Cell death induced by rbf single-mutant clones is mediated by
induction of hid (Moon et al., 2005; Tanaka-Matakatsu et al.,
2009). Inactivation of hid completely abolishes cell death in rbf
mutant clones (Tanaka-Matakatsu et al., 2009). Interestingly,although mutation of hid significantly decreased rbf,gig induced
cell death, some level of cell death was still observed in
rbf,gig,hid triple-mutant clones, particularly in the anterior of
the eye disc (yellow arrows in Figures 2D and 2N, Figures
S2G–S2H). These observations indicate that cell death induced
by mutation of rbf,gig involves both hid-dependent and hid-
independent mechanisms.
Similarly, rbf-induced cell death is highly dependent on Dronc
function (Steele et al., 2009). Whereas dronc mutation signifi-
cantly decreased the death of rbf,gigmutant cells in the posterior
(the differentiating part of the eye disc), inactivation of dronc has
little effect on cell death of rbf,gig clones in the anterior, the
proliferating part of the eye disc (Figure 2E, Figures S2G–S2H).
Therefore anterior and posterior rbf,gig cells displayed a marked
difference in their dependence on dronc for cell death.
Consistent with the observations that inactivation of hid or
dronc partially inhibited cell death in rbf,gigmutant clones, inac-
tivation of hid or dronc in conjunction with rbf and gig mutations
significantly increased the amount of mutant tissue in adult eyes
as well as their overall sizes (Figures 1D, 1E, 1F, 1L, and 1M).
These data also support the idea that that the decreased size
of rbf,gig mutant patches in adult eyes is due to the synergistic
induction of cell death by rbf and gig.
Cell Death Induced by rbf,gig Mutations Requires E2F,
S6K, and Potentially Involves JNK Signaling
Cell death induced by rbfmutation is E2F-dependent (Du, 2000;
Moon et al., 2006). de2f1i2 is a de2f1 mutant that encodesCancer Cell 17, 469–480, May 18, 2010 ª2010 Elsevier Inc. 471
Figure 3. TSC2 Knockdown Induces Cell
Death in Rb Mutant Cancer Cells under
Stress Conditions
(A) Rb mutant DU145 prostate cancer cells were
infected with lentivirus expressing shTSC2 or/and
functional human Rb.
(B and C) Cell death in DU145 cells with different
treatments was measured under the conditions
of hypoxia (B) or 2.5% FBS (C).
(D) Rb-positive PC-3 prostate cancer cells were
infected with lentivirus expressing shTSC2 and/
or shRb.
(E and F) Cell death in PC-3 cells with different
treatments was measured under the condition of
hypoxia (E) or 2.5% FBS (F).
(G and H) Cell growth in 2.5% FBS was measured.
Different cell types and treatments are as indi-
cated.
(I) The mTORC1 inhibitor rapamycin (10 nM) and
pan-caspase inhibitor Z-VAD (100 mM) inhibited
shTSC2-induced cell death in DU145 cells under
hypoxic conditions. In this and in all the subse-
quent figures, pools of lentivirus-infected cells
were used unless indicated otherwise. Error bars
indicate ± SD.
See also Figure S3.
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Specific Killing of Rb Mutant Cancer Cellsa truncated protein missing the C-terminal transactivation and
RBF binding domains. dE2F1i2 protein can still dimerize with
dDP and bind DNA but is unable to activate transcription or
bind RBF (Bosco et al., 2001). Significantly reduced levels of
cell death of rbf,gig mutant clones were observed in the
de2f1i2 background (Figures 2F and 2N). In addition, much larger
rbf,gig double mutant clones were observed in adult eyes
(Figure 1O). These results indicate that dE2F1 activity is required
for the synergistic induction of death of rbf,gig mutant cells.
TSC2 forms a complex with TSC1 to promote GTP hydrolysis
by the small GTPase Rheb. TOR (target of rapamycin) encodes
a large serine/threonine protein kinase that can be found in two
complexes, TORC1 and TORC2. Mutation of gig leads to the
accumulation of theGTP-bound Rheb, which induces the activa-
tion of TORC1/S6K activity and promotes protein synthesis,
metabolism, and cell proliferation. Although mutation of s6k
does not block cell death induced by loss of rbf in the MF area,
mutation of s6k significantly reduced cell death of rbf,gigmutant
cells in both the anterior and the posterior of the developing eye
disc (Figures 2G and 2N) and increased sizes of rbf,gig mutant
clones in adult eyes (Figures 2L and 2M). These observations
show that increased S6K activity is also required for the syner-
gistic induction of cell death of rbf,gig mutants.
The c-Jun N-terminal kinase (JNK) pathway is often involved in
eliminating aberrant cells from Drosophila developing tissues
(Igaki, 2009). Puckered (puc), a dual-specificity phosphatase, is
both a target and a negative regulator of JNK signaling in flies.
Inhibition of JNK signaling by expressing Puc significantly
decreased cell death in rbf,gig double-mutant cells (Figures 2K
and 2P), suggesting the potential involvement of JNK stress472 Cancer Cell 17, 469–480, May 18, 2010 ª2010 Elsevier Inc.signaling in the synergistic induction of death of rbf,gig mutant
cells.
Knockdown of TSC2 in Human Cancer Cells Leads
to Increased Cell Death, Depending on Rb Status
Both the Rb/E2F and the TSC2/TOR signaling pathways are
highly conserved between flies and mammalian systems.
Because Rb is often inactivated in human cancer cells, the
observed synergistic cell death induction by inactivation of Rb
and TSC2 homologs in Drosophila prompted us to determine if
inactivation of TSC2 can specifically induce cell death in Rb
mutant cancer cells.
ShRNA against the C terminus of TSC2 (shTSC2) was shown
to strongly reduce the level of TSC2 (Sun et al., 2008). Consistent
with this, lentivirus containing the shTSC2 construct significantly
reduced the endogenous TSC2 levels in both the Rb mutant
DU145 and Rb-WT PC3 prostate cancer cells (Figures 3A
and 3D). Annexin V and propidium iodide staining were used to
determine the effect of shTSC2 on cell death. Although shTSC2
did not significantly affect cell death under normal culture condi-
tions, significantly elevated levels of cell death were observed in
DU145shTSC2 cells but not in control DU145 or PC3shTSC2 cells
when cells were cultured under hypoxic conditions (Figures 3B
and 3E). In addition, the ability of different shTSC2 constructs
to induce cell death in DU145 cells was correlated with their
ability to decrease the level of TSC2 (Figures S3A and S3B).
Furthermore, the increased death of DU145shTSC2 cells is not
restricted to hypoxic conditions. Significantly elevated levels of
cell death were also observed in DU145shTSC2 but not in
DU145control or PC3shTSC2 cells when cells were cultured in low
Figure 4. TSC2 Knockdown Suppresses
Anchorage-Independent Growth of Rb
Mutant Cancer Cells in Soft Agar and
Reduces Tumor Formation in Xenograft
Models
(A) DU145 cells were infected with lentivirus
expressing shTSC2 and/or human Bcl-XL.
(B) PC-3 cells were infected with lentivirus
expressing shTSC2 and/or shRb.
(C) Control and DU145shTSC2 cells were injected
into nude mice to test their ability to form tumors.
(D and E) Osteosarcoma cells were infected with
lentivirus expressing shTSC2 or control vector.
TSC2 knockdown suppresses the colony forma-
tion of Rb mutant Saos-2 cells but not Rb-WT
MG-63 cells.
(F and G) Breast cancer cells are infected with
lentivirus expressing shTSC2 or control vector.
TSC2 knockdown suppresses the colony forma-
tion of Rb mutant MDA-MB-468 cells but not Rb-
WT MDA-MB-231 cells. Error bars indicate ± SD.
See also Figure S4.
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shTSC2 significantly inhibited proliferation in DU145 cells but not
in PC3 cells (Figures 3G and 3H). Additionally, increased levels of
death in DU145shTSC2 cells were also observed when they were
cultured in soft agar (Figures S3H and S3I). Therefore, knock-
down of TSC2 significantly increased the sensitivity of Rbmutant
DU145 cells to death under a variety of stress conditions.
To demonstrate that shTSC2-induced death in cancer cells is
dependent on the absence of Rb function, we determined the
effect of expressing WT Rb in DU145shTSC2 cells. Expression of
WT Rb protein did not affect the shTSC2-induced decrease in
TSC2 protein level (Figure 3A), but did significantly decrease
shTSC2-induced death in DU145 cells (Figures 3B and 3C) and
partially restored cell proliferation (Figure 3G). Furthermore,
knockdown of Rb using shRb in conjunction with shTSC2 in
PC3 cells significantly increased cell death (Figures 3E and 3F)
and inhibited cell proliferation (Figure 3H). Taken together, these
results demonstrate that cell death induced by shTSC2 is depen-
dent on the absence of Rb function.
Rapamycin was used to determine if shTSC2-induced cell
death in DU145 cells depends on TORC1 signaling. Inhibition
of TORC1 activity by rapamycin significantly decreased
shTSC2-induced cell death (Figure 3I and Figures S3L, S3M).
These results indicate that shTSC2-induced cell death is depen-
dent on increased TORC1 activity. In addition, significantly
decreased levels of cell death were observed when Z-VAD was
used to inhibit caspase activation (Figure 3I and Figures S3J
and S3K). Therefore, shTSC2-induced cell death is largely cas-
pase dependent.
To determine if shTSC2 can also specifically kill other cancer
cells depending on their Rb status, we examined the effect of
shTSC2 on Saos-2 (Rb mutant) and MG-63 (Rb WT) osteosar-
coma cells as well as MDA-MB-468 (Rb mutant) and MDA-
MB-231 (Rb WT) breast cancer cells. ShTSC2 significantlyreduced TSC2 levels in these different cancer cells
(Figure S3C). Interestingly, shTSC2 significantly increased death
in Rb mutant Saos-2 and MDA-MB-468 cancer cells but not in
Rb-WT MG-63 and MDA-MB-231 cancer cells (Figures
S3D–S3G). Therefore, knockdown of TSC2 can induce death in
a variety of cancer cells, depending on Rb status.
ShTSC2 Inhibits the Growth of Rb Mutant Cancer Cells
in Soft Agar and Mouse Xenografts
The ability of cancer cells to grow and form colonies in soft agar
was used to determine if shTSC2-induced changes in the level of
cell death described above correlates with changes in
anchorage-independent growth. As shown in Figure 4, shTSC2
dramatically inhibited the ability of DU145 cells to form colonies
in soft agar (Figure 4A). Similarly, although shTSC2 alone did not
inhibit PC3 cells from forming colonies in soft agar, shRb in
conjunction with shTSC2 did significantly inhibit colony forma-
tion (Figure 4B). These results showed that shTSC2-induced
cell death in these prostate cancer cells is correlated with the
inhibition of cancer cell growth in soft agar.
To further assess whether the correlation between shTSC2-
induced cell death and inhibition of colony formation can be
extended to other cancer cells, the effect of shTSC2 on osteo-
sarcoma and breast cancer cell growthwas determined. shTSC2
significantly inhibited colony formation of Rbmutant cancer cells
(Saos-2 and MDA-MB-468) but not Rb-WT cancer cells (MG-63
and MDA-MB-231) (Figure 4D–4G). These results show that
shTSC2-induced cell death is correlated with an inhibition of
cancer cell growth in soft agar, which is also dependent on the
absence of Rb function.
To determine the in vivo significance of TSC2 knockdown on
tumor growth, a mouse xenograft model was used to evaluate
the effect of TSC2 knockdown. DU145control or DU145shTSC2
cells were injected into athymic nude mice and tumor growthCancer Cell 17, 469–480, May 18, 2010 ª2010 Elsevier Inc. 473
Figure 5. TSC2 Knockdown Induces ROS
Generation
(A) Western blots showing the level of TSC2, phos-
pho-S6K (T389), phospho-Akt (S473), total S6K,
total Akt, and b-Actin in control DU145 cells and
in DU145shTSC2 cells.
(B) Overexpression of constitutively activated
myr-AKT did not inhibit shTSC2-induced cell
death in DU145 cells.
(C and D) DU145shTSC2 cells (D) exhibited signifi-
cantly higher levels of ROS (detected by the fluo-
rescent dye DHE) than control cells (C) grown in
soft agar. Scale bar, 100 mm.
(E) shTSC2 induces ROS generation in DU145
cells grown in complete media. ROS levels were
determined by flow cytometry after staining with
DHE.
(F) PC-3 cells with shTSC2 and/or shRb were
cultured in complete media. ROS levels were
determined by flow cytometry after staining with
the fluorescent dye CM-H2DCFDA.
(G) DU145 cells with shTSC2 and/or re-expressed
Rb were cultured in complete media. The ROS
levels are determined as described in (F). Error
bars indicate ± SD.
Cancer Cell
Specific Killing of Rb Mutant Cancer Cellswas followed. Although all the mice injected with DU145control
cells had tumor growth, only one tumor formed in mice injected
with DU145shTSC2 cells (Figure 4C and Figure S4). Therefore,
shTSC2 also significantly reduced the incidence of tumor
growth in xenograft models. These results, in conjunction with
the previous results of increased cell death and inhibition of
cell growth in soft agar, suggest that inhibition of TSC2 can
potentially be used to specifically target Rb mutant cancer
cells.Overexpression of Activated Akt Does Not Inhibit
ShTSC2-Induced Cell Death
Inactivation of TSC2 leads to the activation of TORC1, which in
turn activates S6K (Wullschleger et al., 2006). S6K has been
shown to form a negative feedback loop with IRS proteins that
leads to inhibition of Akt signaling (Harrington et al., 2004;
Shah et al., 2004). Consistent with this, inactivation of TSC2 or
TSC1 was shown to activate TORC1 but inhibit TORC2 activity,
resulting in the downregulation of Akt signaling (Yang et al.,
2006).
Western blots using antibodies against total or phospho-Akt
(Ser473) were carried out to determine the effect of shTSC2 on
Akt activation in DU145 cells. ShTSC2 led to reduced phos-
pho-Akt and increased phospho-S6K levels without changing
the levels of total Akt or S6K (Figure 5A). Because phosphoryla-
tion on Ser473 is required for the full activation of Akt and Akt is
known to be an important survival signal, we tested the effect of
expressing an activated form of Akt on shTSC2-induced cell
death. Expression of activated Akt did not inhibit shTSC2-
induced cell death (Figure 5B). These observations suggest
that decreased Akt signaling is not likely to be the main cause
of cell death in DU145 cells. Because Akt signaling cannot inhibit
cell death induced by ROS (Nogueira et al., 2008; Robey and
Hay, 2009), we investigated the involvement of oxidative stress
in shTSC2-induced cell death.474 Cancer Cell 17, 469–480, May 18, 2010 ª2010 Elsevier Inc.Inactivation of Rb and TSC2 Synergistically Increase
Oxidative Stress
We used DHE, a dye that detects superoxide, to determine if
shTSC2 induce oxidative stress in DU145 cells. Highly elevated
DHE fluorescence was observed in DU145shTSC2 cells compared
to the DU145control cells grown in soft agar (Figures 5C, 5D). Simi-
larly, FACS analysis detected significantly elevated DHE fluores-
cence in DU145shTSC2 cells grown under normal conditions
(Figure 5E). Therefore, shTSC2 induces significant level of oxida-
tive stress.
RbWTPC3 cells were used to further characterize the effect of
inactivating TSC2 andRb onROS induction. In cells grown under
normoxia, we found that knockdown of either TSC2 or Rb led to
modest but reproducible increases in ROS levels, and that
knockdown of Rb in conjunction with TSC2 led to further
increased ROS levels (Figure 5F). Interestingly, a higher level of
ROS was observed in all the treatment groups under hypoxia,
with the most dramatically increased ROS level observed in
PC3shRb+shTSC2 cells (Figure 5F). These observations show that
hypoxia increased ROS levels and that shRb and shTSC2 led
to a synergistic increase in the level of ROS, which is correlated
with increased death of PC3shRb+shTSC2 cells (compare
Figure 3E, Figure 4B, and Figure 5F).
Similarly, shTSC2 led to a significant increase in ROS levels in
DU145 cells, particularly under hypoxic conditions (Figure 5G).
Furthermore, although expression of WT Rb alone did not
decrease ROS levels, Rb expression significantly decreased
shTSC2-induced ROS levels (Figure 5G). These results show
that inactivation of Rb and TSC2 synergistically increase ROS
levels and that a high level of ROS under hypoxic conditions is
correlated with shTSC2-induced death in Rbmutant cancer cells
(compare Figures 3B, 3C, and 5G).
To test the possibility that stress conditions such as hypoxia
might increase the level of oxidative stress above a certain
threshold to promote shTSC2-induced cell death, we deter-
mined the effect of increasing oxidative stress by addition of
Figure 6. ShTSC2-Induced Cell Death Is Mediated by the Induction of ROS
(A) The effect of shTSC2 and Rb on H2O2-induced cell death in DU145 cells. Cells were cultured in complete media and were treated with 800 mMH2O2 for 24 hr
before assaying for cell death.
(B) The effect of rapamycin (10 nM), G418 (400 mg/ml), DPI (5 mM), and NAC (5mM) on ROS levels in control and DU145shTSC2 with or without Rb expression. Cells
were cultured under hypoxic conditions for 24 hr and assayed for ROS by FACS.
(C) NAC (5 mM) suppressed shTSC2 -induced cell death in DU145 under hypoxic conditions.
(D) NAC (5 mM) suppressed the death of PC-3shTSC2+shRb cells under hypoxic conditions.
(E) Overexpression of the ROS-scavenging enzymes SOD2 or catalase inhibited the death of DU145shTSC2 cells under hypoxic conditions.
(F) The effect of DPI (5 mM) on cell death in DU145shTSC2 and DU145shTSC2+Rb cells.
(G) Overexpression of either SOD2 or catalase restored the ability of DU145shTSC2 cells to form colonies in soft agar.
(H) NAC (10 mM) restored the ability of DU145shTSC2 cells to form colonies in soft agar.
(I) NAC (10 mM) restored the ability of PC-3shTSC2+shRb cells to form colonies in soft agar.
(J and K) G418 represses death induced by shTSC2 in DU145 cells under hypoxic conditions (J) but increases death in DU145 cells that are induced by H2O2 (K).
Error bars indicate ± SD.
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Specific Killing of Rb Mutant Cancer CellsH2O2 into the culture media. At concentrations of H2O2 that
induced a low level of cell death in DU145control cells, high levels
of cell death were observed in DU145shTSC2 cells (Figure 6A).
Expression of Rb in DU145shTSC2 cells decreased oxidative
stress (Figure 6B) and also decreased H2O2-induced cell death
(Figure 6A). These results show that DU145shTSC2 cells are
much more sensitive to oxidative stress, and suggest that stress
conditions such as hypoxia contribute to shTSC2-induced cell
death, at least in part, by increasing oxidative stress.Reducing Oxidative Stress Significantly Decreases
shTSC2-Induced Cell Death and Increases Cancer Cell
Growth in Soft Agar
The above observations suggest that cell death induced by inac-
tivation of both Rb and TSC2 is due to synergistically induced
oxidative stress. To test this idea, the antioxidant N-acetyl
cysteine (NAC) was used to reduce oxidative stress. Addition
of NAC significantly reduced ROS levels (Figure 6B) and
significantly reduced death in DU145shTSC2 cells (Figure 6C).Cancer Cell 17, 469–480, May 18, 2010 ª2010 Elsevier Inc. 475
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PC3shRb+shTSC2 cells (Figure 6D). In addition, reducing oxidative
stress by expressing the ROS scavenger enzymes SOD2 or
catalase also significantly decreased the level of shTSC2-
induced death in DU145 cells (Figure 6E). Interestingly, expres-
sion of Rb in DU145 cells significantly reduced shTSC2-induced
ROS and cell death, which is not significantly decreased further
by antioxidants (Figure 6B and 6F). These observations strongly
support the ideas that oxidative stress is a critical mediator of cell
death in DU145 cells and that Rb plays a critical role regulating
ROS when TSC2 is inactivated.
Cell growth in soft agar was used to further determine the
effect of reducing oxidative stress on shTSC2-induced inhibition
of cancer cell growth. Although expression of SOD2 or catalase
did not increase colony growth in DU145control cells, SOD2 or
catalase expression in DU145shTSC2 cells significantly increased
colony growth in soft agar (Figure 6G). Similarly, reducing oxida-
tive stress by NAC dramatically increased the growth of
DU145shTSC2 but not DU145control cells in soft agar (Figure 6H).
Furthermore, NAC treatment also dramatically increased the
colony growth of PC3shRb+shTSC2 cells but not the PC3control cells
(Figure 6I). In conclusion, these results provide further support
for the idea that oxidative stress induced by Rb and TSC2
inactivation contributes to increased cancer cell death and
growth inhibition.
Inhibition of Protein Synthesis Reduces
ShTSC2-Induced Oxidative Stress and Cell Death
Inhibition of TORC1 by rapamycin significantly inhibited shTSC2-
induced cell death (Figure 3I and Figures S3L, S3M). Because
the above results showed that shTSC2-induced cell death is,
at least in part, due to increased oxidative stress, we determined
the effect of rapamycin on ROS levels. Indeed, rapamycin signif-
icantly reduced ROS levels in DU145shTSC2 cells without signifi-
cantly affecting the ROS levels in control cells (Figure 6B).
Because a key function of TORC1 is to stimulate protein
synthesis, we determined the effect of inhibiting protein
synthesis on shTSC2-induced cell death and oxidative stress.
G418 interferes with the function of 80S ribosomes and inhibits
protein synthesis in eukaryotic cells. Interestingly, G418 signifi-
cantly reduced ROS levels in DU145shTSC2 cells but not in
DU145control cells (Figure 6B). Furthermore, although G418 treat-
ment significantly reduced shTSC2-induced cell death
(Figure 6J), it did not suppress H2O2-induced cell death in
DU145 cells (Figure 6K). These results show that the ability of
G418 to inhibit shTSC2-induced cell death is correlated with its
ability to decrease oxidative stress, and suggest that increased
protein synthesis contributes to shTSC2-induced oxidative
stress and cell death.
SOD2 Contributes to Rb Inactivation-Induced ROS
Levels and Cell Death
To investigate how inactivation of Rb induces oxidative stress
synergistically with shTSC2, we examined the effect of Rb on
ROS scavenger enzyme expression. Although the level of
SOD2 was very low in control and DU145shTSC2 cells, signifi-
cantly higher levels of SOD2were detected whenWTRbwas ex-
pressed (Figure 7A). Interestingly, under hypoxic conditions,
shTSC2 led to further increased levels of SOD2 only in the pres-476 Cancer Cell 17, 469–480, May 18, 2010 ª2010 Elsevier Inc.ence of WT Rb (Figure 7A). Therefore, Rb regulates the basal as
well as shTSC2-induced SOD2 levels in DU145 cells. The
inability of DU145shTSC2 cells to induce SOD2 under hypoxic
conditions was correlated with high level of oxidative stress
and increased cell death (Figures 5G and 3B). We also tested
the effect of Rb on SOD2 levels in PC3 cells. ShTSC2 led to
elevated SOD2, particularly under hypoxic conditions
(Figure 7B). Interestingly, shRb blocked shTSC2-induced
increase in SOD2 levels without affecting the basal SOD2 levels
(Figure 7B). The inability of PC3shRb+shTSC2 cells to induce SOD2
is also correlated with high levels of oxidative stress and
increased cell death (Figures 5F and 3E).
To further test the idea that SOD2 contributes to shTSC2-
induced cell death, we used shRNA to knockdown SOD2 in
PC3 cells (Figure S5A). Although shTSC2 or shSOD2 alone
did not significantly affect cell death in PC3 cells,
shTSC2+shSOD2 significantly increased the level of cell death
(Figure 7C), which is correlated with significantly increased
ROS levels (Figure S5B). Furthermore, whereas the expression
of Rb significantly inhibited shTSC2-induced cell death in
DU145 cells (Figure 3B), similar levels of cell death are
observed between the DU145shTSC2 and the
DU145shTSC2+Rb+shSOD2 cells (Figure 7D). These results provide
strong evidence that SOD2 is a critical target of Rb that contrib-
utes to Rb and TSC2 inactivation-induced cell death. However,
because shRb+shTSC2 induces a higher level of cell death
than shSOD2+shTSC2 does in PC3 cells (compare Figures
3E and 7C), it is likely that additional targets of Rb also
contribute to Rb and TSC2 inactivation-induced death in these
cells.
shTSC2 Inhibits De Novo Lipid Synthesis, Decreases
Survival Signaling, and Induces ER Stress
To further characterize the mechanisms that contribute to
shTSC2-induced cell death and the acquisition of resistance,
we recovered cells from a tumor that developed in a mouse in-
jected with DU145shTSC2 cells. Analysis of these cells showed
that the TSC2 protein level was still significantly reduced
although not as dramatically as that in DU145shTSC2 cells
(Figure S5C). However, these cells had regained the ability to
grow in soft agar and are resistant to cell death under hypoxia
(data not shown). Therefore it appears that these cells have
acquired resistance to shTSC2-induced cell death and we refer
to these cells as DU145shTSC2-adapt cells.
Microarray experiments were carried out to identify genes
that were significantly altered in response to shTSC2 but
were restored in DU145shTSC2-adapt cells. A total of 463 genes
showed significant upregulation or downregulation in response
to shTSC2. The expression of 170 genes from these 463 was
reversed in the adapted cells. These include genes involved
in the cell cycle, lipid metabolism, and cell survival signaling
such as Bcl-XL and components of the insulin-like growth
factor/EGFR/PI3K signaling (Figure S5D). The expression of
some of the genes was verified by Real-time reverse transcrip-
tion polymerase chain reaction (RT-PCR) (Figures 7E and 7J). A
general agreement was observed between the RT-PCR results
and the microarray data. For example, Bcl-XL, the insulin-like
growth factor IGF1R, and key enzymes for de novo lipid
synthesis such as ACLY, HMGCS1, and ACACA, were all
Figure 7. Inactivation of Both Rb and TSC2 Leads to Decreased Survival Signaling and Defective ROS Control
(A and B) Western blots showing that shTSC2 induced increased SOD2 levels under hypoxic conditions in an Rb-dependent manner. DU145 cells (A) and PC-3
cells (B) were cultured in normoxic or hypoxic conditions for 24 hr.
(C) PC3 cells infected with lentivirus expressing shTSC2 and/or shSOD2 as indicated. Cell death was determined after culturing under hypoxic conditions for
48 hr.
(D) Similar levels of death are observed in DU145shTSC2 and DU145shTSC2+Rb+shSOD2 cells, indicating shSOD2 blocks the ability of Rb to inhibit death in
DU145shTSC2 cells.
(E–J) mRNA levels of Bcl-XL, IGF1R, ACLY, HMGCS1, ACACA and CycE1were determined by Real-time PCR. DU145control, DU145shTSC2, and DU145shTSC2-adapt
cells were cultured under hypoxic conditions for 24 hr and total RNA was extracted for RT-PCR analysis.
(K) Overexpression of Bcl-XL reduces shTSC2-induced death in DU145 cells under hypoxic conditions.
(L) The inhibition of lipid synthesis induces ROS generation in DU145 cells. Cerulenin is an inhibitor of fatty acid synthase and mevastatin is an inhibitor of HMG
reductase.
(M) RT-PCR shows increased XBP-1 splicing in DU145shTSC2 cells as compared with DU145control and DU145shTSC2-adapt cells.
(N) A model for synergistic cell death induction by Rb and TSC2 inactivation in cancer cells. Error bars indicate ± SD.
See also Figure S5.
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DU145shTSC2-adapt cells. In fact, the expression of Bcl-XL,
HMGCS1, ACACA, and ACLY were actually higher in the adap-
ted cells (Figures 7E and 7I). On the other hand, increased cy-
clin E expression was detected in DU145shTSC2 cells but not in
DU145shTSC2-adapt cells (Figure 7J). Expression of Bcl-XL
strongly inhibited shTSC2-induced cell death (Figure 7K) and
restored cell growth in soft agar (Figure 4A), suggesting that
changes in the expression of Bcl-XL may contribute to
shTSC2-induced cell death in DU145shTSC2 cells and the resis-
tance to death in DU145shTSC2-adapt cells.Cancer cells generally synthesize most of their lipids de novo.
Inhibition of ACL inhibits de novo lipid synthesis and suppresses
tumor cell growth (Hatzivassiliou et al., 2005; Pearce et al., 1998).
In addition, inhibition of fatty acid or cholesterol synthesis
induces cell death in several cancer models (De Schrijver et al.,
2003; Demierre et al., 2005). To examine the possibility that the
decreased expression of genes involved in lipid synthesis may
contribute to shTSC2-induced cell death, we examined the
effect of inhibiting fatty acid or cholesterol synthesis on ROS
levels. Inhibition of fatty acid synthesis by Cerulenin led to
increased ROS levels (Figure 7L), consistent with a publishedCancer Cell 17, 469–480, May 18, 2010 ª2010 Elsevier Inc. 477
Cancer Cell
Specific Killing of Rb Mutant Cancer Cellsreport (Migita et al., 2009). Similarly, inhibition of cholesterol
synthesis by Mevastatin also increased ROS (Figure 7L). Taken
together, these results suggest that inhibition of de novo lipid
synthesis may also contribute to the shTSC2-induced cell death
by increasing oxidative stress.
The significantly decreased expression of genes involved in
lipid synthesis in conjunction with increased protein synthesis
raises the possibility that shTSC2 will induce additional cellular
stress in these cells. Indeed increased XBP-1 splicing is
observed in DU145shTSC2 cells as compared with the DU145con-
trol or DU145shTSC2-adapt cells (Figure 7M), suggesting that ER
stress is also induced by shTSC2 in DU145 cells and that
reduced level of ER stress is correlated with the resistance of
DU145shTSC2-adapt cells to shTSC2-induced cell death. Activa-
tion of ER stress can induce cell death through multiple path-
ways (Ron and Walter, 2007). Taken together, our results
suggest that inactivation of Rb and TSC2 induces multiple
cellular stresses that contribute to synergistic cell death.
DISCUSSION
Because Rb is a tumor suppressor that is often inactivated in
cancers, approaches that specifically kill Rb mutant cells can
potentially lead to targeted cancer therapies. From a genetic
screen in Drosophila, we showed that inactivation of Rb and
TSC2 homologs induced cell death synergistically in normal
developing tissues. We further showed that inactivation of
TSC2 specifically kills Rb mutant cancer cells and inhibited
cancer cell growth in soft agar and in xenograft models. These
results suggest that TSC2 can potentially be used to specifically
target Rb mutant cancers.
Germline mutations of either TSC2 or TSC1 will cause
tuberous sclerosis complex, which is an autosomal dominant
disorder characterized by benign tumor formation in a variety
of organs (reviewed in Crino et al., 2006). Therefore, inhibition
of TSC2 may cause some side effects. However, because the
onset of TSC2 inactivation-induced cell death is rapid, short-
term inactivation of TSC2 will be sufficient to induce specific
killing of Rb mutant cancer cells. Therefore, it is possible that
specific killing of cancer cells without significant side effects
can be achieved simply by adjusting the time period of TSC2
inactivation.
How Does Rb and TSC2 Inactivation Induce Synergistic
Cell Death?
Our results suggest that Rb and TSC2 inactivation-induced
synergistic cell death is mediated by the high level of cellular
stress (see model in Figure 7N). Inactivation of TSC2 deregulates
TORC1 activity, which promotes protein synthesis and increases
mitochondria oxidative phosphorylation. These activities of
TORC1 potentially induce a number of cellular stresses,
including metabolic stress and oxidative stress. The observed
inhibition of lipid synthesis is potentially a consequence of meta-
bolic stress induced by shTSC2 and will lead to even higher
levels of oxidative stress (Figure 7L). In addition, because cancer
cells are generally dependent on de novo lipid synthesis
(Hatzivassiliou et al., 2005), an inhibition of lipid synthesis in
conjunction with increased protein synthesis will induce
increased ER stress in cancer cells (Little et al., 2007; Ozcan478 Cancer Cell 17, 469–480, May 18, 2010 ª2010 Elsevier Inc.et al., 2008). Indeed both oxidative stress and ER stress are
induced by shTSC2 in Rb mutant cancer cells. Furthermore,
TSC2 inactivation inhibits autophagy as well as aggresome
formation, which limits the ability of these cells to counteract
misfolded protein and ER stress (Kubota, 2009; Zhou et al.,
2009). Therefore, inactivation of TSC2 in cancer cells induces
multiple types of cellular stress. Our results in this study show
that oxidative stress plays an important role in Rb and TSC2
inactivation-induced cell death.
Induction of cancer cell death by shTSC2 is dependent on the
absence of Rb function. It appears that Rb plays a critical role in
determining the sensitivity of cells to shTSC2-induced cellular
stress. Rb/E2F has been implicated in the expression of several
important stress regulators, including SOD2, GRP78, and
AMPKa2, which modulates oxidative stresses, ER stress, and
energy stress, respectively (Hallstrom et al., 2008; Racek et al.,
2008; Tanaka et al., 2002). We show here that the inability of
Rb mutant cancer cells to induce SOD2 sensitized these cells
to shTSC2-induced cell death. Further studies will be needed
to determine if AMPKa2 and GRP78 are regulated by Rb in
cancer cells and contribute to shTSC2-induced cancer cell
killing. Our observations that ER stress is activated by shTSC2
in Rb mutant cancer cells and that shTSC2 induces significant
cell death in Rb mutant cells under a variety of stress conditions
suggest multiple types of cellular stress contribute to synergistic
cell death.
The mechanism by which cellular stresses induce death is
complex and is not entirely clear. ROS is a typical indicator of
oxidative stress and can induce cell death by damaging themito-
chondria membrane or by inducing JNK signaling or other
cellular stresses. On the other hand, oxidative stress can also
result from other cellular stresses, such as metabolic stress
and ER stress, which are also induced by shTSC2 in Rb mutant
cancer cells. In addition, ER stress can also induce cell death
through CHOP, ER-associated initiator caspases, or JNK
signaling independent of ROS. Therefore it is possible that
multiple pathways contribute to synergistic cell death within
the same cell. This is consistent with the observation that
shTSC2 can specifically kill a variety of Rb mutant cancers
despite the loss of p53, Pten, or the presence of oncogenic Ras.
Our model that increased cellular stress mediates synergistic
cell death induced by Rb and TSC2 inactivation is also consis-
tent with the results obtained in flies. Similar to the observation
in human cancer cells, the synergistic cell death in the devel-
oping fly tissues is mediated by the Rb/E2F and the TSC2/TOR
signaling pathways and requires a high level of protein synthesis.
Decreasing the level of protein synthesis significantly inhibits the
synergistic cell death. Furthermore, inhibition of JNK signaling,
which is activated by various cellular stresses, decreased syner-
gistic cell death of the rbf,gig double-mutant clones. Therefore,
the synergistic cell death of rbf,gig double-mutant clones also
involves cellular stress.
Cancers Resistant to TSC2 Inactivation
The proposed model also suggests how Rb mutant cancer cells
may acquire resistance to TSC2 inactivation-induced cell death.
Because oncogenic Ras or PI3K/Akt will promote ROS-medi-
ated cell death, simply activating these survival signals is not
likely to be sufficient for resistant cancer to develop. On the other
Cancer Cell
Specific Killing of Rb Mutant Cancer Cellshand, changes in the expression of genes that can reduce
cellular stress and genes that can increase survival signaling
without increasing oxidative stress may lead to the development
of resistant cancers. Indeed, increased expression of key
enzymes in lipid synthesis, increased Bcl-XL expression, and
restoration of the EGFR and PI3K survival signaling is observed
in the resistant cancer cells. It appears that these combined
changes inhibit cell death by reducing the level of cellular stress,
including ER stress and oxidative stress, and by increasing the
level of survival signaling.
The development of resistant cancers is a common problem
for targeted therapies. For example, even for successful targeted
therapies such as imatinib and gefitinib, resistant cancers even-
tually develop. It is worth pointing out that very few therapeutic
agents are curative in human cancer treatment when delivered
alone. Most chemotherapeutic agents are delivered in combina-
tion when cures are achieved. Considering the possible involve-
ment of the Bcl-2 family of cell death inhibitors in the develop-
ment of resistant cancers and the contribution of cellular stress
in the killing of cancer cells, it will be interesting to determine
the effect of a Bcl-2 family inhibitor, such as ABT-737, or agents
that can increase cellular stress, such as inhibitors of lipid
synthesis or activators of AMPK, on shTSC2-induced cell death.
Subsets of Rb-Deficient Cancers that Are Sensitive
to TSC2 Inactivation
It is interesting to note that cancer cells with different mecha-
nisms of Rb inactivation exhibit different responses to TSC2
inactivation. Rb is inactivated in cancer cells by mutation, loss
of expression, or by functional inactivation. We showed that
shTSC2 specifically kills Rb mutant cancer cells. Furthermore,
shRNA against Rb sensitized Rb-WT cancer cells to shTSC2-
induced cell death. These results indicate that inactivation of
TSC2 can be used to kill cancer cells that have either mutated
or silenced Rb. On the other hand, MG-63 cells, which have
WT Rb but deleted p16INK4a and p14ARF (Park et al., 2002), are
resistant to shTSC2-induced cell death. Therefore, cancer cells
that carry WT Rb that is functionally inactivated by mutation of
p16 may be resistant to TSC2 inactivation. It is likely that muta-




DU145, PC-3, Saos-2, MG-63, MDA-MB-231, and MDA-MB-468 cells were
obtained from the American Type Culture Collection. The DU145shTSC2-adapt
cell line was generated by dissociating cells from the tumor developed in
a mouse injected with DU145shTSC2 cells. All the cells were maintained in
Dulbecco’s modified Eagle’s medium supplemented with 10% fetal bovine
serum (FBS, Atlas Biologicals), 50 IU penicillin/streptomycin (Gemini Bio-Prod-
ucts), and 2 mmol/l L-glutamine (Invitrogen) in a humidified atmosphere with
5% CO2 at 37
C. Hypoxic studies were carried out at 1% oxygen.
Drosophila Genetics and Assays
See Supplemental Experimental Procedures for details.
FACS Analysis of Cell Death and ROS
Quantification of cell death was performed using FACScan (BD Biosciences)
after cells were stained with Annexin V-FITC and propidium iodide according
to manufacture’s specifications.See Supplemental Experimental Procedures for details.
Soft Agar Growth Assay
For colony formation, 104 cells suspended in 0.35% agarose solution were
poured over hard-bottomed agar (0.6%) previously solidified in 6-well plates.
Cells were cultured in a humidified atmosphere with 5% CO2 at 37
C for 4-6
weeks, and then colonies were counted.
Western Blot
After desired treatments as specified in the Results section, cells were washed
twice with PBS and lysed in buffer (20 mM Tris-HCl [pH 7.5], 150 mM NaCl, 1
mM EDTA, 1% Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM b-glycer-
ophosphate, 1 mM sodium vanadate, 1 mg/ml leupeptin, 1 mM phenylmethyl-
sulfonylfluoride). Equal amounts of protein were loaded. Western detection
was carried out using a Li-Cor Odyssey image reader. The goat anti-mouse
immunoglobulin G (IgG) and goat anti-rabbit IgG secondary antibodies were
obtained from Li-Cor.
Xenograft Experiments
The animal protocol was approved by the Institutional Animal Care and Use
Committee at the University of Chicago. Male nude mice (Hsd: Athymic
Nude-Foxnlnu, aged 4-6 weeks on arrival) were purchased fromHarlan. A total
of 5 3 106 cells were injected into the flanks of mice for tumor development.
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